The Endocannabinoid System: Implications in Gastrointestinal Physiology and Pathology

Area of Science:

• Gastroenterology and Metabolic Science
• Endocannabinoid System Research

Background:

• The endocannabinoid system (ECS) is crucial for gastrointestinal and liver physiology and pathology.
• Cannabinoid receptors (CB1R, CB2R) and endocannabinoids (AEA, 2-AG) regulate gut motility, inflammation, and metabolism.

Purpose of the Study:

• To review the role of the ECS in gastrointestinal and metabolic diseases.
• To highlight the therapeutic potential of targeting the ECS for conditions such as obesity, NAFLD, IBS, and colorectal cancer.

Main Methods:

• Literature review of recent studies on the ECS in gastrointestinal and metabolic diseases.
• Analysis of therapeutic strategies targeting CB1R and CB2R.

Main Results:

• The ECS modulates appetite, body weight, and inflammation, impacting obesity, NAFLD, and IBS.
• Targeting peripheral CB1R antagonists and CB2R agonists shows efficacy in treating intestinal inflammation, hepatic steatosis, and IBS symptoms.
• The ECS is a potential target for colorectal cancer therapy, influencing cell proliferation and apoptosis.

Conclusions:

• The ECS presents a significant opportunity for developing innovative therapeutic strategies for gastrointestinal and metabolic disorders.
• A targeted approach to modulating the ECS is essential for optimizing treatment efficacy and minimizing side effects.